Weekly Anesthesiology Research Analysis
This week’s anesthesiology literature was dominated by practice-changing randomized trials and pragmatic innovations: a multicenter randomized trial (Lancet) showed lower-intensity anticoagulation (low‑dose UFH or therapeutic LMWH) is noninferior to standard-dose UFH during ECMO and trends toward less bleeding; a multicenter randomized trial (JAMA Surgery) demonstrated single-encounter augmented-reality–guided lung nodule localization is noninferior to standard CT-guided workflows while markedly
Summary
This week’s anesthesiology literature was dominated by practice-changing randomized trials and pragmatic innovations: a multicenter randomized trial (Lancet) showed lower-intensity anticoagulation (low‑dose UFH or therapeutic LMWH) is noninferior to standard-dose UFH during ECMO and trends toward less bleeding; a multicenter randomized trial (JAMA Surgery) demonstrated single-encounter augmented-reality–guided lung nodule localization is noninferior to standard CT-guided workflows while markedly reducing radiation, pain, and delays; and a randomized, double‑blind BJA trial found lateral quadratus lumborum block (alone or with intrathecal morphine) improves early post‑cesarean analgesia. Together these papers point to de-escalation of invasive practices, workflow-accelerating technologies, and refinements in regional analgesia.
Selected Articles
1. Standard-dose unfractionated heparin versus low-dose unfractionated heparin and low-molecular-weight heparin in extracorporeal life support (RATE): an open-label, randomised, non-inferiority trial.
A multicenter randomized non-inferiority trial (n=320 analyzed at 6 months) compared standard‑dose UFH to low‑dose UFH and therapeutic LMWH during ECMO. Both lower-intensity strategies met noninferiority for a composite of severe bleeding, severe thromboembolism, or 6‑month mortality and showed numerical reductions in severe bleeding without excess thrombotic events, supporting reconsideration of anticoagulation targets in ECMO.
Impact: First adequately powered randomized trial addressing anticoagulation intensity in ECMO, directly influencing a ubiquitous ICU practice and offering a pathway to reduce bleeding-related harm.
Clinical Implications: Centers may consider lower-intensity anticoagulation (low-dose UFH or LMWH) for ECMO patients who lack definitive indications for full anticoagulation, implementing close monitoring and tailored protocols while awaiting further subgroup analyses.
Key Findings
- Low-dose UFH and therapeutic LMWH were noninferior to standard-dose UFH for the composite outcome (severe bleeding, severe thromboembolism, or 6‑month mortality).
- Severe bleeding rates trended lower with low-dose UFH (58%) and LMWH (59%) vs standard-dose UFH (65%) without increased severe thromboembolism.
- Six‑month mortality was numerically lower in the lower-intensity groups (standard 50% vs low-dose 42% vs LMWH 44%).
2. Single-Encounter Augmented Reality-Guided Localization for Resection of Suspected Early-Stage Lung Cancer: A Randomized Clinical Trial.
A multicenter randomized noninferiority trial (modified ITT n=270) found that single-encounter AR-guided percutaneous localization performed in the OR under general anesthesia was noninferior to standard multiple-encounter CT-guided localization for successful sublobar resection. AR guidance markedly reduced radiation exposure, preprocedural pain, puncture time, and localization‑to‑incision delays while maintaining localization accuracy.
Impact: Demonstrates a practical OR-based AR workflow that preserves surgical outcomes while improving patient experience, radiation safety, and operational efficiency—an immediate candidate for implementation studies.
Clinical Implications: Thoracic surgery teams can consider AR-guided single-encounter localization to reduce radiation and patient discomfort and to streamline scheduling; ensure training, margin protocols, and validation across systems before widespread adoption.
Key Findings
- Successful sublobar resection: AR 98.5% vs CT 99.3% (noninferior).
- Substantial reductions in radiation (median 456.5 vs 1260.1 mGy·cm), preprocedural pain (NRS 0 vs 5), puncture time (0.63 vs 6.50 min), and localization-to-incision interval (2.0 vs 33.5 min).
- Localization error and surgical margins were comparable; CT-guided group had pneumothorax in 29.4%.
3. Comparison of intrathecal morphine, lateral quadratus lumborum block, and their combination for analgesia and quality of recovery after Caesarean delivery: a randomised, double-blind, two-centre clinical trial.
A randomized, double‑blind two‑centre trial (n=58) compared bilateral lateral QLB, 100 μg intrathecal morphine (ITM), and their combination. QLB reduced early (6‑hour) resting pain versus ITM, and ITM+QLB further reduced early resting and coughing pain as well as worst pain at 24 hours. QoR-40 noninferiority was inconclusive; opioid use and PONV were similar, with mild increases in pruritus for QLB-containing regimens.
Impact: A rigorous double-blind RCT informing neuraxial opioid versus abdominal wall block strategies for Cesarean analgesia and showing additive analgesic benefit when combined.
Clinical Implications: Consider adding lateral QLB to intrathecal morphine for enhanced early analgesia after Cesarean or using QLB when neuraxial opioids are contraindicated, while monitoring for mild pruritus and confirming effects in larger trials.
Key Findings
- QLB reduced 6‑hour resting pain compared with intrathecal morphine (mean difference 2.9; P<0.001).
- ITM+QLB further reduced early resting and coughing pain and worst pain at 24 h versus ITM alone; opioid consumption and PONV were similar.
- Noninferiority for QoR-40 at 24 h between QLB and ITM was inconclusive in this small trial.